On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.
Zanvastro is the first FDA‑approved therapy for Alexander disease and the first treatment that directly targets the protein accumulation that drives disease progression.
Zanvastro has received multiple designations including Orphan Drug, Fast Track, Breakthrough Therapy, Rare Pediatric Disease, and a Priority Review Voucher, reflecting the severity and rarity of Alexander disease and the FDA’s commitment to advancing therapies for rare diseases.
Milestone: Ending the Era of No Approved Options
“For patients with Alexander disease and their families, there have never been any approved treatment options – the disease progresses relentlessly, and they could only receive supportive care,” said Emily Freilich, M.D., Director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research.
“Today’s approval is a milestone for this patient community, bringing the first therapy that addresses the underlying cause of this rare and serious disease.”
Disease Background: GFAP Protein Accumulation Causes Neurological Damage
Alexander disease is a rare, progressive neurological disorder caused by mutations in the gene encoding glial fibrillary acidic protein (GFAP).
When this protein is abnormal, it accumulates in the brain’s supporting cells, damaging the nervous system over time.
With an estimated incidence of less than one per million, the disease can cause a range of severe and even life‑threatening problems, including seizures, regression of developmental milestones, difficulty walking, muscle weakness, and increased intracranial pressure.
Mechanism of Action and Administration
Zanvastro is an antisense oligonucleotide that works by reducing the production of abnormal GFAP protein, curbing it before it can accumulate and cause further damage.
The drug is administered by trained healthcare professionals via lumbar puncture (intrathecal injection) once every three months.
Clinical Efficacy Evidence: Covers a Broad Age Range from Infants to Adults
The efficacy and safety of Zanvastro were evaluated in a multicenter, randomized, controlled clinical study (NCT04849741) that included 49 children and adults with Alexander disease aged 2 years and older, along with an open‑label substudy that included 4 patients younger than 2 years.
Given the extreme rarity of the disease and the wide age range of patients, the FDA comprehensively reviewed the available evidence to support approval covering patients from infants through adults.
Patients Aged 5 Years and Older
Among those with measurable walking impairment at baseline, patients treated with Zanvastro for 61 weeks showed a significantly better walking speed compared to the untreated group.
Children Aged 2 to 4 Years
Because walking speed is not a reliable indicator of progression in this age group, the study used a more comprehensive motor function assessment (including standing, walking, running, and jumping).
Results showed that treated children improved on this measure, while the control group declined.
Patients Younger Than 2 Years
Due to the rarity of the disease and the lack of concurrent controls, direct clinical trial data are limited.
Pharmacokinetic modeling confirmed that drug concentrations at the same dose in this age group are expected to be comparable to those in older children; safety data from the 4 patients younger than 2 years in the study, together with safety observations in older children, also support this conclusion.
These approaches allowed the approval to extend to the youngest patients while maintaining the evidentiary standards required for approval.
Common Side Effects and Precautions
The most common adverse reactions included vomiting, back pain, cough, headache, and post‑lumbar puncture syndrome.
Patients and caregivers should inform their healthcare provider if the patient develops symptoms consistent with meningitis, as aseptic meningitis has been reported in patients receiving Zanvastro.
Patients and physicians should carefully review the full prescribing information when making treatment decisions.
